Shire boosts rare disease portfolio with Lumena buy

The London-listed pharmaceuticals group Shire has bolstered its rare disease drug pipeline with the acquisition of the US biopharmaceutical company Lumena Pharmaceuticals. As well as its late stage rare disease…